Home  About the Journal Editorial Board Aims & Scope Peer Review Policy Subscription Contact Us
Early Edition  //  Current Issue  //  Archives  //  Most Read  //  Most Downloaded  //  Most Cited

Medicine Research ›› 2020, Vol. 4 ›› Issue (3): 200014-.DOI: 10.21127/yaoyimr20200014

Special Issue: COVID-19

• Hotspots • Previous Articles     Next Articles

Hydroxychloroquine for the Treatment of Coronavirus Disease 2019: Evidence, Possible Mode of Action and Industrial Supply

Mario Pagliaro*,a and Francesco Meneguzzo*,b   

  1. a Istituto per lo Studio dei Materiali Nanostrutturati, CNR, via U. La Malfa 153, 90146 Palermo, Italy
    b Istituto per la Bioeconomia, CNR, via Madonna del Piano 10, 50019 Sesto Fiorentino FI, Italy
  • Received:2020-06-30 Online:2020-09-22 Published:2020-09-22
  • Contact: Mario Pagliaro, Email: mario.pagliaro@cnr.it; Francesco Meneguzzo, Email: francesco.menguzzo@cnr.it

Abstract: Hydroxychloroquine, a known antiviral metabolite of chloroquine, is increasingly used along with antibiotic azithromycin for the treatment of COVID-19 infection. In about one month, India, the world’s largest manufacturer, delivered the pharmaceutical ingredient for treating COVID-19 to over 50 countries. Coupled to azithromycin, the therapy is being used across the world both for patients staying at home at the early phase of symptoms, as well as for patients hospitalized. We summarize achievements as of late April 2020, review possible modes of action and suggest avenues for the quick scale-up of production of hydroxychloroquine.

Key words: hydroxychloroquine, coronavirus disease 2019, immunomodulator, cytokine storm, flow chemistry

Copyright © Medicine Research, All Rights Reserved.
Address: 425 East 76th Street, Apt 9E, New York, NY, 10021, United States